Urine C-peptide creatinine ratio is an alternative to stimulated serum C-peptide measurement in late-onset, insulin-treated diabetes

Diabetic Medicine

Volumn 28, Issue 9, 2011, Pages 1034-1038

  Jones, A G ^a,b   Besser, R E J ^a   Mcdonald, T J ^a,b   Shields, B M ^a   Hope, S V ^a,b   Bowman, P ^a,b   Oram, R A ^a,b   Knight, B A ^a   Hattersley, A T ^a,b  

^a UNIVERSITY OF EXETER   (United Kingdom)

^b ROYAL DEVON AND EXETER HOSPITAL   (United Kingdom)

Author keywords

B cell; C peptide; Diabetes; Insulin secretion

Indexed keywords

C PEPTIDE; CREATININE; INSULIN; ORAL ANTIDIABETIC AGENT;

ARTICLE; CREATININE URINE LEVEL; DIABETES MELLITUS; DIAGNOSTIC VALUE; FEMALE; GLOMERULUS FILTRATION RATE; GOLD STANDARD; HORMONE URINE LEVEL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ONSET AGE; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; URINALYSIS;

AGE OF ONSET; AGED; C-PEPTIDE; CREATININE; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; FASTING; FEMALE; GLUCAGON; GLUCOSE TOLERANCE TEST; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; MIDDLE AGED; SENSITIVITY AND SPECIFICITY;

EID: 80051660576     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2011.03272.x     Document Type: Article

References (23)

1. Polonsky K, Frank B, Pugh W, Addis A, Karrison T, Meier P et al. The limitations to and valid use of C-peptide as a marker of the secretion of insulin. Diabetes 1986; 35: 379-386.
2. Clark PM. Assays for insulin, proinsulin(s) and C-peptide. Ann Clin Biochem 1999; 36: 541-564.
3. Gjessing HJ, Matzen LE, Faber OK, Froland A. Fasting plasma C-peptide, glucagon stimulated plasma C-peptide, and urinary C-peptide in relation to clinical type of diabetes. Diabetologia 1989; 32: 305-311.
4. Koskinen P, Viikari J, Irjala K, Kaihola HL, Seppala P. Plasma and urinary C-peptide in the classification of adult diabetics. Scand J Clin Lab Invest 1986; 46: 655-663.
5. Lee A, Morley J. Classification of type2 diabetes by clinical response to metformin-troglitazone combination and C-peptide criteria. Endocr Pract 1999; 5: 305-313.
6. Hother-Nielsen O, Faber O, Sorensen NS, Beck-Nielsen H. Classification of newly diagnosed diabetic patients as insulin-requiring or non-insulin-requiring based on clinical and biochemical variables. Diabetes Care 1988; 11: 531-537.
7. Madsbad S, Krarup T, McNair P, Christiansen C, Faber OK, Transbol I et al. Practical clinical value of the C-peptide response to glucagon stimulation in the choice of treatment in diabetes mellitus. Acta Med Scand 1981; 210: 153-156.
8. Grant PJ, Barlow E, Miles DW. Plasma C-peptide levels identify insulin-treated diabetic patients suitable for oral hypoglycaemic therapy. Diabet Med 1984; 1: 284-286.
9. Lee A, Bray GA, Morley JE. Stimulated C-peptide and glucose levels as metabolic criteria to use insulin treatment in adult-onset typeII diabetes. Endocr Pract 1996; 2: 183-190.
10. Munshi MN, Hayes M, Sternthal A, Ayres D. Use of serum C-peptide level to simplify diabetes treatment regimens in older adults. Am J Med 2009; 122: 395-397.
11. Frazier LM, Mulrow CD, Alexander LT Jr, Harris RT, Heise KR, Brown JT et al. Need for insulin therapy in typeII diabetes mellitus. A randomized trial. Arch Intern Med 1987; 147: 1085-1089.
12. Laakso M, Sarlund H, Korhonen T, Voutilainen E, Majander H, Hakala P et al. Stopping insulin treatment in middle-aged diabetic patients with high post-glucagon plasma C-peptide. Effect on glycaemic control, serum lipids and lipoproteins. Acta Med Scand 1988; 223: 61-68.
13. Hoekstra JB, Van Rijn HJ, Thijssen JH, Erkelens DW. C-peptide reactivity as a measure of insulin dependency in obese diabetic patients treated with insulin. Diabetes Care 1982; 5: 585-591.
14. Hohberg C, Pfutzner A, Forst T, Lubben G, Karagiannis E, Borchert M et al. Successful switch from insulin therapy to treatment with pioglitazone in type2 diabetes patients with residual beta-cell function: results from the PioSwitch study. Diabetes Obes Metab 2009; 11: 464-471.
15. Hermann LS, Schersten B, Melander A. Anti-hyperglycaemic efficacy, response prediction and dose-response relations of treatment with metformin and sulphonylurea, alone and in primary combination. Diabet Med 1994; 11: 953-960.
16. Berger B, Stenstrom G, Sundkvist G. Random C-peptide in the classification of diabetes. Scand J Clin Lab Invest 2000; 60: 687-693.
17. Service FJ, Rizza RA, Zimmerman BR, Dyck PJ, O'Brien PC, Melton LJ 3rd. The classification of diabetes by clinical and C-peptide criteria. A prospective population-based study. Diabetes Care 1997; 20: 198-201.
18. Horwitz DL, Rubenstein AH, Katz AI. Quantitation of human pancreatic beta-cell function by immunoassay of C-peptide in urine. Diabetes 1977; 26: 30-35.
19. Aoki Y. Variation of endogenous insulin secretion in association with treatment status: assessment by serum C-peptide and modified urinary C-peptide. Diabetes Res Clin Pract 1991; 14: 165-173.
20. McDonald TJ, Knight BA, Shields BM, Bowman P, Salzmann MB, Hattersley AT. Stability and reproducibility of a single-sample urinary C-peptide/creatinine ratio and its correlation with 24-h urinary C-peptide. Clin Chem 2009; 55: 2035-2039.
21. Greenbaum CJ, Mandrup-Poulsen T, McGee PF, Battelino T, Haastert B, Ludvigsson J et al. Mixed-meal tolerance test versus glucagon stimulation test for the assessment of beta-cell function in therapeutic trials in type1 diabetes. Diabetes Care 2008; 31: 1966-1971.
22. Marena S, Montegrosso G, De Michieli F, Pisu E, Pagano G. Comparison of the metabolic effects of mixed meal and standard oral glucose tolerance test on glucose, insulin and C-peptide response in healthy, impaired glucose tolerance, mild and severe non-insulin-dependent diabetic subjects. Acta Diabetol 1992; 29: 29-33.
23. Steffes MW, Sibley S, Jackson M, Thomas W. Beta-cell function and the development of diabetes-related complications in the Diabetes Control and Complications Trial. Diabetes Care 2003; 26: 832-836.